Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 2

Results For "trade-generics"

14 News Found

Cipla has strong traction in India and the US: ICICI Direct
News | January 31, 2022

Cipla has strong traction in India and the US: ICICI Direct

ICICI Direct’s analysis of Cipla’s Q3FY22 results

Cipla’s Q3FY22 PAT at Rs 729 cr.
News | January 26, 2022

Cipla’s Q3FY22 PAT at Rs 729 cr.

Cipla announced its unaudited consolidated financial results for quarter ended December 31st, 2021.

Windlas Biotech opens for subscription this week
Biotech | August 02, 2021

Windlas Biotech opens for subscription this week

Proceeds from the IPO will be used for the expansion of the Dehradun facility.

Steady performance; for Alkem Laboratories: ICICI Securities
News | February 13, 2021

Steady performance; for Alkem Laboratories: ICICI Securities

The company continued to maintain clear FDA status across its plants and has received 12 ANDA approvals during 9MFY21

Upcoming E-conference
July 17, 2026 Biosimilars & Biologics: The Next Growth Frontiers for Indian Pharma

Latest Stories

India's clinical research ambitions need more than regulatory reforms: Experts

Health Ministry proposes faster licensing timelines for medical device manufacturers

India to launch revamped Anemia Mukt Bharat Abhiyaan with expanded 7x7x7 strategy

White Papers

Chasing Consistency: Centralizing operations data is the key to optimizing chemicals plants

Implementing a digital transformation in chemical operations to maximize profitability

The complexity of compliance

The Sprint to the Summit: Unlocking Lab Efficiency through Digital Transformation

The guiding role of fluidized and spouted bed technologies in particle building processes

Interviews
Peptides are next frontline therapeutics led by GLP-1: Dr. Vandana Singh, Head - API Regulatory Sciences, Biocon Limited
Peptides are next frontline therapeutics led by GLP-1: Dr. Vandana Singh, Head - API Regulatory Sciences, Biocon Limited
Rising pharma demand driving our India market strategy: Sanjeev Kumar Khandelwal, Head of Division, Characterization Division, Anton Paar India
Rising pharma demand driving our India market strategy: Sanjeev Kumar Khandelwal, Head of Division, Characterization Division, Anton Paar India
India is becoming centre of innovation and global execution: Sanjay Vyas, President and MD, Parexel India
India is becoming centre of innovation and global execution: Sanjay Vyas, President and MD, Parexel India
Sanjay Vyas President and Managing Director, Parexel India And Global SBU Head- Safety services & Logistics, Parexel International

Packaging